Investor memorandum
A focused pre-seed plan for AngioPatch™ validation.
A technical overview of platform rationale, capital allocation, validation milestones, and principal development risks.
Market context
A significant unmet need, viewed with diligence.
TAM — Global oncology
$243B
by 2025 (Precedence Research)
SAM — Angiogenesis inhibitors
$15.7B
2024 (Strategic Market Research)
CAGR — Inhibitor market
14%
2025–2033 (Data Insights)
Pre-seed
Advancing AngioPatch™ from concept to validated preclinical platform.
Pre-seed capital will support prototype development, angiogenesis assay validation, IP strategy, scientific advisory expansion, and preclinical planning.
Capital is milestone-directed. No specific funding target is presented on this public overview.
Use of proceeds
Prototype development & platform engineering35%
In vitro angiogenesis assays & biological validation25%
Preclinical planning & regulatory strategy20%
IP, partnerships & scientific advisory network12%
Operations & company formation8%
Validation plan
Milestones tied to evidence, not calendar theater.
| Phase | Milestone | Diligence output |
|---|---|---|
| 01 | Prototype architecture | Material design inputs and release-profile specification |
| 02 | Biological validation | In vitro angiogenesis assay package and reproducibility review |
| 03 | Preclinical planning | Model selection, endpoints, CRO scope, and regulatory pathway |
| 04 | Platform readiness | IP position, advisory network, and partner diligence materials |
Data room
Structured materials for qualified review
Platform thesis, literature review, proposed assay plan, development roadmap, and company formation materials are available through direct inquiry.